You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameVildagliptin
Accession NumberDB04876
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionVildagliptin, previously identified as LAF237, is a new oral anti-hyperglycemic agent (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. Vildagliptin inhibits the inactivation of GLP-1 and GIP by DPP-4, allowing GLP-1 and GIP to potentiate the secretion of insulin in the beta cells and suppress glucaon release by the alpha cells of the islets of Langerhans in the pancreas. It is currently in clinical trials in the U.S. and has been shown to reduce hyperglycemia in type 2 diabetes mellitus. While the drug is still not approved for use in the US, it was approved in Feb 2008 by European Medicines Agency for use within the EU and is listed on the Australian PBS with certain restrictions.
Structure
Thumb
Synonyms
EQUA
Galvus
Jalra
LAF 237
LAF-237
LAF237
NVP-LAF-237
NVP-LAF237
Vildagliptin
Xiliarx
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
GalvusTablet50 mgOralNovartis Europharm Limited2007-09-26Not applicableEu
GalvusTablet50 mgOralNovartis Europharm Limited2007-09-26Not applicableEu
GalvusTablet50 mgOralNovartis Europharm Limited2007-09-26Not applicableEu
GalvusTablet50 mgOralNovartis Europharm Limited2007-09-26Not applicableEu
GalvusTablet50 mgOralNovartis Europharm Limited2007-09-26Not applicableEu
GalvusTablet50 mgOralNovartis Europharm Limited2007-09-26Not applicableEu
GalvusTablet50 mgOralNovartis Europharm Limited2007-09-26Not applicableEu
GalvusTablet50 mgOralNovartis Europharm Limited2007-09-26Not applicableEu
GalvusTablet50 mgOralNovartis Europharm Limited2007-09-26Not applicableEu
GalvusTablet50 mgOralNovartis Europharm Limited2007-09-26Not applicableEu
GalvusTablet50 mgOralNovartis Europharm Limited2007-09-26Not applicableEu
JalraTablet50 mgOralNovartis Europharm Limited2008-11-19Not applicableEu
JalraTablet50 mgOralNovartis Europharm Limited2008-11-19Not applicableEu
JalraTablet50 mgOralNovartis Europharm Limited2008-11-19Not applicableEu
JalraTablet50 mgOralNovartis Europharm Limited2008-11-19Not applicableEu
JalraTablet50 mgOralNovartis Europharm Limited2008-11-19Not applicableEu
JalraTablet50 mgOralNovartis Europharm Limited2008-11-19Not applicableEu
JalraTablet50 mgOralNovartis Europharm Limited2008-11-19Not applicableEu
JalraTablet50 mgOralNovartis Europharm Limited2008-11-19Not applicableEu
JalraTablet50 mgOralNovartis Europharm Limited2008-11-19Not applicableEu
JalraTablet50 mgOralNovartis Europharm Limited2008-11-19Not applicableEu
JalraTablet50 mgOralNovartis Europharm Limited2008-11-19Not applicableEu
XiliarxTablet50 mgOralNovartis Europharm Limited2008-11-19Not applicableEu
XiliarxTablet50 mgOralNovartis Europharm Limited2008-11-19Not applicableEu
XiliarxTablet50 mgOralNovartis Europharm Limited2008-11-19Not applicableEu
XiliarxTablet50 mgOralNovartis Europharm Limited2008-11-19Not applicableEu
XiliarxTablet50 mgOralNovartis Europharm Limited2008-11-19Not applicableEu
XiliarxTablet50 mgOralNovartis Europharm Limited2008-11-19Not applicableEu
XiliarxTablet50 mgOralNovartis Europharm Limited2008-11-19Not applicableEu
XiliarxTablet50 mgOralNovartis Europharm Limited2008-11-19Not applicableEu
XiliarxTablet50 mgOralNovartis Europharm Limited2008-11-19Not applicableEu
XiliarxTablet50 mgOralNovartis Europharm Limited2008-11-19Not applicableEu
XiliarxTablet50 mgOralNovartis Europharm Limited2008-11-19Not applicableEu
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
GalvusNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIII6B4B2U96P
CAS number274901-16-5
WeightAverage: 303.3993
Monoisotopic: 303.194677059
Chemical FormulaC17H25N3O2
InChI KeySYOKIDBDQMKNDQ-XWTIBIIYSA-N
InChI
InChI=1S/C17H25N3O2/c18-9-14-2-1-3-20(14)15(21)10-19-16-5-12-4-13(6-16)8-17(22,7-12)11-16/h12-14,19,22H,1-8,10-11H2/t12?,13?,14-,16?,17?/m0/s1
IUPAC Name
(2S)-1-{2-[(3-hydroxyadamantan-1-yl)amino]acetyl}pyrrolidine-2-carbonitrile
SMILES
OC12CC3CC(C1)CC(C3)(C2)NCC(=O)N1CCC[[email protected]]1C#N
Pharmacology
IndicationUsed to reduce hyperglycemia in type 2 diabetes mellitus.
Structured Indications Not Available
PharmacodynamicsVildagliptin belongs to a class of orally active antidiabetic drugs (DPP-IV inhibitors) that appear to have multiple functional benefits beyond simple blood-glucose control. One of these is a potential protective effect on pancreatic beta cells, which deteriorate in diabetes. Vildagliptin appears to be safe, very well tolerated, and efficacious. Following a meal, gut incretin hormones are released. The most important incretin hormones are GLP-1 and glucose-dependent insulinotropic polypeptide (GIP). These hormones, secreted in the human small intestine, are responsible for insulin release due to increased glucose levels. In contrast to agents that promote insulin secretion via glucose-independent mechanisms, GLP-1's dependence on glucose concentration is considered beneficial due to a lower risk of hypoglycemia. GLP-1 also inhibits glucagon secretion and increases beta cell mass by stimulating proliferation and neogenesis. However, the clinical utility of GLP-1 is limited by its short half-life (2 minutes). GLP-1 is rapidly degraded by the proteolytic enzyme DPP-IV. To enhance GLP-1 activity, inhibition of the DPP-IV enzyme is emerging as a novel therapeutic approach in the treatment of diabetes. Administration of vildagliptin enhances GLP-1's ability to produce insulin in response to elevated concentrations of blood glucose, inhibit the release of glucagon following meals, slow the rate of nutrient absorption into the bloodstream, slow the rate of gastric emptying, and reduce food intake.
Mechanism of actionVildagliptin inhibits dipeptidyl peptidase-4 (DPP-4). This in turn inhibits the inactivation of GLP-1 by DPP-4, allowing GLP-1 to potentiate the secretion of insulin in the beta cells. Dipeptidyl peptidase-4's role in blood glucose regulation is thought to be through degradation of GIP and the degradation of GLP-1.
TargetKindPharmacological actionActionsOrganismUniProt ID
Dipeptidyl peptidase 4Proteinyes
inhibitor
HumanP27487 details
Related Articles
AbsorptionRapidly absorbed following oral administration with an oral bioavailability of greater than 90%.
Volume of distributionNot Available
Protein binding9.3%
MetabolismNot Available
Route of eliminationNot Available
Half lifeThe elimination half-life is approximately 90 minutes.
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Vildagliptin.Approved, Investigational
AcetohexamideVildagliptin may increase the hypoglycemic activities of Acetohexamide.Withdrawn
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Vildagliptin.Approved, Investigational
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Vildagliptin.Approved, Illicit, Investigational
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Vildagliptin.Experimental
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Vildagliptin.Illicit, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Vildagliptin.Approved
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Vildagliptin.Approved
AripiprazoleThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Aripiprazole.Approved, Investigational
Arsenic trioxideThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Arsenic trioxide.Approved, Investigational
ArticaineThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Articaine.Approved
AsenapineThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Asenapine.Approved
AtazanavirThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Atazanavir.Approved, Investigational
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Vildagliptin.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Benazepril.Approved, Investigational
BendroflumethiazideThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Bendroflumethiazide.Approved
BetamethasoneThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Betamethasone.Approved, Vet Approved
BoceprevirThe serum concentration of Vildagliptin can be decreased when it is combined with Boceprevir.Approved
BrexpiprazoleThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Brexpiprazole.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Vildagliptin.Approved, Investigational
BumetanideThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Bumetanide.Approved
BuserelinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Buserelin.Approved
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Vildagliptin.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Candoxatril.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Captopril.Approved
CarbamazepineThe metabolism of Vildagliptin can be increased when combined with Carbamazepine.Approved, Investigational
CeritinibThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Ceritinib.Approved
ChlorothiazideThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Chlorotrianisene can be decreased when it is combined with Vildagliptin.Withdrawn
ChlorpropamideVildagliptin may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorthalidoneThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Chlorthalidone.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Cilazapril.Approved
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Vildagliptin.Approved, Investigational, Withdrawn
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Vildagliptin.Approved
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Vildagliptin.Approved, Vet Approved
ClozapineThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Clozapine.Approved
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Vildagliptin.Approved
CorticotropinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Corticotropin.Approved, Vet Approved
Cortisone acetateThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Cortisone acetate.Approved
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Vildagliptin.Approved
CyclophosphamideThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Vildagliptin.Approved, Investigational, Vet Approved
Cyproterone acetateThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Cyproterone acetate.Approved, Investigational
DabrafenibThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Dabrafenib.Approved
DanazolThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Danazol.Approved
DarunavirThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Darunavir.Approved
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Vildagliptin.Approved
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Vildagliptin.Approved
DesogestrelThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Desogestrel.Approved
DexamethasoneThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Dexamethasone.Approved, Investigational, Vet Approved
DiazoxideThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Diazoxide.Approved
DienestrolThe serum concentration of Dienestrol can be decreased when it is combined with Vildagliptin.Approved
DienogestThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Dienogest.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Vildagliptin.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Vildagliptin.Approved
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Vildagliptin.Approved
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Vildagliptin.Approved
DisopyramideVildagliptin may increase the hypoglycemic activities of Disopyramide.Approved
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Vildagliptin.Approved
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Vildagliptin.Approved
DrospirenoneThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Drospirenone.Approved
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Vildagliptin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Enalaprilat.Approved
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Vildagliptin.Approved, Investigational
EpinephrineThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Epinephrine.Approved, Vet Approved
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Vildagliptin.Approved
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Vildagliptin.Approved
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Vildagliptin.Approved
EsmirtazapineThe serum concentration of Esmirtazapine can be increased when it is combined with Vildagliptin.Investigational
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Vildagliptin.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Estramustine can be decreased when it is combined with Vildagliptin.Approved
Estrogens, esterifiedThe serum concentration of Estrogens, esterified can be decreased when it is combined with Vildagliptin.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Vildagliptin.Approved
Etacrynic acidThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Etacrynic acid.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Vildagliptin.Approved
Ethynodiol diacetateThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Ethynodiol diacetate.Approved
EtonogestrelThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Etonogestrel.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Vildagliptin.Approved
EverolimusThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Everolimus.Approved
FludrocortisoneThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Fludrocortisone.Approved
FosamprenavirThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Fosamprenavir.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Fosinopril.Approved
FurosemideThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Furosemide.Approved, Vet Approved
GarlicThe serum concentration of Vildagliptin can be decreased when it is combined with Garlic.Approved
GlibornurideVildagliptin may increase the hypoglycemic activities of Glibornuride.Withdrawn
GliclazideVildagliptin may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideVildagliptin may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideVildagliptin may increase the hypoglycemic activities of Glipizide.Approved
GliquidoneVildagliptin may increase the hypoglycemic activities of Gliquidone.Approved
GlisoxepideVildagliptin may increase the hypoglycemic activities of Glisoxepide.Approved
GlyburideVildagliptin may increase the hypoglycemic activities of Glyburide.Approved
GoserelinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Goserelin.Approved
HexestrolThe serum concentration of Hexestrol can be decreased when it is combined with Vildagliptin.Withdrawn
HistrelinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Histrelin.Approved
HydrochlorothiazideThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Hydrochlorothiazide.Approved, Vet Approved
HydrocortisoneThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Hydroflumethiazide.Approved
Hydroxyprogesterone caproateThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Hydroxyprogesterone caproate.Approved
IloperidoneThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Iloperidone.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Imidapril.Investigational
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Vildagliptin.Approved
IndapamideThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Indapamide.Approved
IndinavirThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Indinavir.Approved
Insulin AspartVildagliptin may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirVildagliptin may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineVildagliptin may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineVildagliptin may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanVildagliptin may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproVildagliptin may increase the hypoglycemic activities of Insulin Lispro.Approved
Insulin PorkVildagliptin may increase the hypoglycemic activities of Insulin Pork.Approved
LanreotideThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Lanreotide.Approved
LeuprolideThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Leuprolide.Approved, Investigational
LevonorgestrelThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Levonorgestrel.Approved, Investigational
Lipoic AcidLipoic Acid may increase the hypoglycemic activities of Vildagliptin.Approved, Nutraceutical
LisinoprilThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Lisinopril.Approved, Investigational
LopinavirThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Lopinavir.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Vildagliptin.Approved, Investigational
LurasidoneThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Lurasidone.Approved
MecaserminVildagliptin may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
Medroxyprogesterone acetateThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
Megestrol acetateThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Megestrol acetate.Approved, Vet Approved
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Vildagliptin.Approved
MethallenestrilThe serum concentration of Methallenestril can be decreased when it is combined with Vildagliptin.Experimental
MethotrimeprazineThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Methotrimeprazine.Approved
MethyclothiazideThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Methyclothiazide.Approved
MethylprednisoloneThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Methylprednisolone.Approved, Vet Approved
MetolazoneThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Metolazone.Approved
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Vildagliptin.Approved, Illicit
MifepristoneVildagliptin may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Vildagliptin.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Moexipril.Approved
NateglinideVildagliptin may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Vildagliptin.Approved, Withdrawn
NelfinavirThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Nelfinavir.Approved
NiacinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Niacin.Approved, Investigational, Nutraceutical
NilotinibThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Nilotinib.Approved, Investigational
NorethisteroneThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Norethisterone.Approved
NorgestimateThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Norgestimate.Approved
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Vildagliptin.Approved
OctreotideThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Octreotide.Approved, Investigational
OlanzapineThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Olanzapine.Approved, Investigational
OmapatrilatThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Omapatrilat.Investigational
OpipramolThe serum concentration of Opipramol can be increased when it is combined with Vildagliptin.Investigational
PaliperidoneThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Paliperidone.Approved
PasireotideThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Pasireotide.Approved
PentamidineThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Pentamidine.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Perindopril.Approved
PethidineThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Pethidine.Approved
PimozideThe serum concentration of Pimozide can be increased when it is combined with Vildagliptin.Approved
PiperazineThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Piperazine.Approved, Vet Approved
PipotiazineThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Pipotiazine.Approved
PolythiazideThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Polythiazide.Approved
PrednisoloneThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Prednisolone.Approved, Vet Approved
PrednisoneThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Prednisone.Approved, Vet Approved
ProgesteroneThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Progesterone.Approved, Vet Approved
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Vildagliptin.Approved
QuetiapineThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Quinapril.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Quinethazone.Approved
QuinineVildagliptin may increase the hypoglycemic activities of Quinine.Approved
RamiprilThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Ramipril.Approved
RepaglinideVildagliptin may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RescinnamineThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Rescinnamine.Approved
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Vildagliptin.Approved
RisperidoneThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Risperidone.Approved, Investigational
RitonavirThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Ritonavir.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Vildagliptin.Approved
SaquinavirThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Saquinavir.Approved, Investigational
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Vildagliptin.Approved, Investigational
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Vildagliptin.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Vildagliptin.Approved
SirolimusThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Sirolimus.Approved, Investigational
SpiraprilThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Spirapril.Approved
St. John's WortThe metabolism of Vildagliptin can be increased when combined with St. John's Wort.Nutraceutical
SulfadiazineVildagliptin may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleVildagliptin may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfisoxazoleVildagliptin may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SunitinibVildagliptin may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Vildagliptin.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Vildagliptin.Approved, Investigational
TacrolimusThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Tacrolimus.Approved, Investigational
TemocaprilThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Temocapril.Experimental, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Temsirolimus.Approved
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Vildagliptin.Approved
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Vildagliptin.Approved
TipranavirThe serum concentration of Vildagliptin can be decreased when it is combined with Tipranavir.Approved, Investigational
TolazamideVildagliptin may increase the hypoglycemic activities of Tolazamide.Approved
TolbutamideVildagliptin may increase the hypoglycemic activities of Tolbutamide.Approved
TorasemideThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Trandolapril.Approved
TriamcinoloneThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Triamcinolone.Approved, Vet Approved
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Vildagliptin.Approved
TrichlormethiazideThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Trichlormethiazide.Approved, Vet Approved
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Vildagliptin.Approved
TriptorelinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Triptorelin.Approved, Vet Approved
Valproic AcidThe serum concentration of Valproic Acid can be decreased when it is combined with Vildagliptin.Approved, Investigational
VerapamilThe metabolism of Verapamil can be decreased when combined with Vildagliptin.Approved
VorinostatThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Vorinostat.Approved, Investigational
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Vildagliptin.Approved
ZiprasidoneThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Ziprasidone.Approved
Food InteractionsNot Available
References
Synthesis Reference

Stephen Winter, Jordi Bosch, Jordi Puig Serrano, Jose Javier Soto, “PROCESS FOR PREPARING VILDAGLIPTIN.” U.S. Patent US20080167479, issued July 10, 2008.

US20080167479
General References
  1. Balas B, Baig MR, Watson C, Dunning BE, Ligueros-Saylan M, Wang Y, He YL, Darland C, Holst JJ, Deacon CF, Cusi K, Mari A, Foley JE, DeFronzo RA: The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab. 2007 Apr;92(4):1249-55. Epub 2007 Jan 23. [PubMed:17244786 ]
External Links
ATC CodesA10BH02A10BD08
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9313
Blood Brain Barrier+0.7886
Caco-2 permeable-0.6768
P-glycoprotein substrateSubstrate0.6301
P-glycoprotein inhibitor IInhibitor0.5624
P-glycoprotein inhibitor IIInhibitor0.9723
Renal organic cation transporterNon-inhibitor0.6373
CYP450 2C9 substrateNon-substrate0.7472
CYP450 2D6 substrateNon-substrate0.6984
CYP450 3A4 substrateSubstrate0.5965
CYP450 1A2 substrateNon-inhibitor0.8627
CYP450 2C9 inhibitorNon-inhibitor0.6428
CYP450 2D6 inhibitorNon-inhibitor0.7168
CYP450 2C19 inhibitorNon-inhibitor0.6922
CYP450 3A4 inhibitorNon-inhibitor0.866
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5
Ames testNon AMES toxic0.7053
CarcinogenicityNon-carcinogens0.8895
BiodegradationNot ready biodegradable0.9959
Rat acute toxicity2.4274 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.853
hERG inhibition (predictor II)Inhibitor0.6939
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
TabletOral50 mg
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility1.75 mg/mLALOGPS
logP1.12ALOGPS
logP-0.22ChemAxon
logS-2.2ALOGPS
pKa (Strongest Acidic)14.71ChemAxon
pKa (Strongest Basic)9.03ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area76.36 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity82 m3·mol-1ChemAxon
Polarizability33.17 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as alpha amino acid amides. These are amide derivatives of alpha amino acids.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentAlpha amino acid amides
Alternative Parents
Substituents
  • Alpha-amino acid amide
  • N-acylpyrrolidine
  • Cyclohexylamine
  • Tertiary carboxylic acid amide
  • Tertiary alcohol
  • Pyrrolidine
  • Cyclic alcohol
  • Tertiary amine
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Secondary amine
  • Nitrile
  • Carbonitrile
  • Secondary aliphatic amine
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Alcohol
  • Aliphatic heteropolycyclic compound
Molecular FrameworkAliphatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Virus receptor activity
Specific Function:
Cell surface glycoprotein receptor involved in the costimulatory signal essential for T-cell receptor (TCR)-mediated T-cell activation. Acts as a positive regulator of T-cell coactivation, by binding at least ADA, CAV1, IGF2R, and PTPRC. Its binding to CAV1 and CARD11 induces T-cell proliferation and NF-kappa-B activation in a T-cell receptor/CD3-dependent manner. Its interaction with ADA also ...
Gene Name:
DPP4
Uniprot ID:
P27487
Molecular Weight:
88277.935 Da
References
  1. Ahren B, Gomis R, Standl E, Mills D, Schweizer A: Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care. 2004 Dec;27(12):2874-80. [PubMed:15562200 ]
  2. Mentlein R, Gallwitz B, Schmidt WE: Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem. 1993 Jun 15;214(3):829-35. [PubMed:8100523 ]
  3. Gupta R, Walunj SS, Tokala RK, Parsa KV, Singh SK, Pal M: Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Curr Drug Targets. 2009 Jan;10(1):71-87. [PubMed:19149538 ]
Comments
comments powered by Disqus
Drug created on October 20, 2007 05:50 / Updated on August 17, 2016 12:24